Ute von Wangenheim, MD, PhD

Principal Statistician
Boehringer Ingelheim International GmbH, Germany

Poster(s):

• (301) Zongertinib in patients with pretreated human epidermal growth factor receptor 2-mutant advanced non–small cell lung cancer: Beamion LUNG-1
  Wednesday, October 29, 2025